Paired tVNS With ERP in OCD
ConditionOCD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorUniversity of Florida
About this trial
In the proposed investigation, the investigator will develop pilot data for the use of tVNS (transcutaneous vagal nerve stimulation) to enhance efficacy of exposure and response prevention therapy (ERP) to improve treatment success in patients with OCD. This data will include tolerability information from therapists and patients with OCD, effect sizes on real world clinical outcomes for the combinatory treatment, and mechanistic data on brain changes associated with treatment.
Eligibility criteria
Qualifiers
Adults between the ages of 18 and 55
Meet DSM-5 criteria for OCD, based on a structured clinical interview and who have a YBOCS score of 15 or higher, indicating at least moderate OCD severity
Participants must be willing and able to provide informed consent.
Disqualifiers
Participants with major neurological conditions, autism spectrum disorder, psychosis, major uncorrected sensory deficit, and severe medical disease that may be associated with neurological effects.
People with an active eating disorder that requires treatment, but we will not exclude people who are in remission.
Current illicit or prescription drug abuse
Participants who are receiving pharmacotherapy for their OCD or for other psychiatric disorders will not be excluded
Trial design
Treatments tested in this trial
- Sham
- tVNS
Treatment groups
56 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Florida
Lead sponsor
International OCD Foundation
Collaborator
Source ClinicalTrials.gov